These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Perry CM Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583 [TBL] [Abstract][Full Text] [Related]
27. Treatment of HIV infection with the CCR5 antagonist maraviroc. Kromdijk W; Huitema AD; Mulder JW Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558 [TBL] [Abstract][Full Text] [Related]
28. FDA notifications. Accelerated approval for raltegravir tablets. AIDS Alert; 2007 Dec; 22(12):143-4. PubMed ID: 18411485 [No Abstract] [Full Text] [Related]
29. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials. Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911 [No Abstract] [Full Text] [Related]
31. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697 [No Abstract] [Full Text] [Related]
32. New drugs offer options. AIDS Read; 2007 Apr; 17(4):206. PubMed ID: 17479506 [No Abstract] [Full Text] [Related]
33. Maraviroc: a review of its use in HIV infection and beyond. Woollard SM; Kanmogne GD Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256 [TBL] [Abstract][Full Text] [Related]
34. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use. Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238 [TBL] [Abstract][Full Text] [Related]
35. An in-depth look at the challenges of prescribing maraviroc. Edmunds-Ogbuokiri T HIV Clin; 2008; 20(3):9-11. PubMed ID: 18814378 [No Abstract] [Full Text] [Related]
37. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467 [TBL] [Abstract][Full Text] [Related]
38. Novel HIV treatment approved. Groeschen HM Am J Health Syst Pharm; 2007 Sep; 64(18):1886. PubMed ID: 17823091 [No Abstract] [Full Text] [Related]
39. Report from the XVI International HIV Drug Resistance Workshop. Kuritzkes DR AIDS Clin Care; 2007 Aug; 19(8):69-70. PubMed ID: 17695089 [No Abstract] [Full Text] [Related]
40. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"]. Zorn F MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]